• Exozymes priced a placement of 35,555 units at USD 18 per unit, each with two common shares and one warrant.
• Deal issued 71,110 shares, 35,555 warrants; gross proceeds USD 639,990, net proceeds earmarked for NCT development, R&D, corporate uses.
• Placement agent MDB Capital earned USD 44,799 commission; received a warrant for 10,666 shares at USD 11.24, exercisable Dec. 30, 2026.
• Investor warrants carry a USD 11.24 strike; become exercisable June 5, 2027; expire June 5, 2031; redemption possible if shares trade at USD 17.98.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exozymes Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-031560), on July 01, 2026, and is solely responsible for the information contained therein.